Table 2. Overall survival (OS), disease free survival (DFS) and median month's survival of ERO1A, OSBPL3 and IFI44L.
| Overall Survival Kaplan-Meier Estimate | ||||
|---|---|---|---|---|
| total cases | cases deceased | median months survival | Logrank Test P-Value | |
| ERO1A upregulated | 59 | 41 | 15.11 | p=0.0004894 |
| ERO1A downregulated | 118 | 51 | 22.7 | |
| OSBPL3 upregulated | 96 | 61 | 17.02 | p= 0.00397 |
| OSBPL3 downregulated | 81 | 31 | 29.99 | |
| IFI44L upregulated | 55 | 34 | 17.48 | p= 0.0155 |
| IFI44L downregulated | 122 | 58 | 21.88 | |
| Disease Free Survival Kaplan-Meier Estimate | ||||
| total cases | cases relapsed | median months disease free | Logrank Test P-Value | |
| ERO1A upregulated | 45 | 34 | 11.93 | p=0.0005923 |
| ERO1A downregulated | 93 | 47 | 20.37 | |
| OSBPL3 upregulated | 71 | 52 | 13.67 | p= 0.00121 |
| OSBPL3 downregulated | 67 | 29 | 25.89 | |
| IFI44L upregulated | 40 | 25 | 13.04 | p= 0.0814 |
| IFI44L downregulated | 98 | 56 | 17.28 | |